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On March 27, 2008, the American Thyroid Association sponsored a research summit on the Thyroid and
Metabolism. The goals of the summit were to explore emerging new concepts and potential therapies arising
from recent insights into the action of thyroid hormone signaling. New advances have identified functions
previously thought to be distinct from thyroid hormone signaling pathways and suggest new avenues of
therapy for metabolic disease.Introduction
Thyroid hormone has long been recognized as a major contribu-
tor to human metabolism. Indeed, in his opening remarks to the
research summit convened by the American Thyroid Association
in March of 2008 on this topic, Mitchell Lazar from the University
of Pennsylvania reviewed the seminal observations of the surgi-
cal pioneer and Nobel Laureate Emil Kocher, who in 1883 des-
cribed a syndrome of extreme fatigue and lack of growth in
a young girl whose thyroid he had removed. This early descrip-
tion of profound hypothyroidism or myxedema led to the pio-
neering experiments of George R. Murray, who in 1891 proved
that this disorder was curable by administration of sheep thyroid
extract. Together, these initial ‘‘loss- and gain-of-function’’
experiments demonstrated the importance of thyroid hormone
in human metabolism and disease.
While thyroid hormone therapy is now used to treat millions of
people worldwide, the exact role of thyroid hormone in regulating
human metabolism remains imperfectly understood. Indeed, as
discussed at the research summit, recent advances in elucidat-
ing the systemic and local regulation of thyroid hormone produc-
tion as well as its actions in a variety of target tissues have shed
new light on the role of thyroid hormone in body weight regula-
tion, insulin signaling, and lipid homeostasis. In addition, the
development of thyroid hormone analogs may yield novel
treatments for hypercholesterolemia. Together, these advances
herald an era of opportunity for understanding the role of thyroid
hormone in human metabolism and applying it to the develop-
ment of new drugs for metabolic disease.
Thyroid Hormone Receptors and Metabolism
While the thyroid gland produces predominantly thyroxine (T4),
the primary biologically active form of the hormone is triidothyr-
onine (T3), which binds to and activates the thyroid hormone
receptor, a ligand-regulated transcription factor (Figure 1). In
key early studies in the early 1960s, Jamshed Tata suggested
that T3 action in stimulating basal metabolic rate in rats was me-
diated by changes in mRNA expression and could be inhibited
using actinomycin D. Introduced by Douglas Forrest (National
Institutes of Health), we now know of three major thyroid
hormone receptor isoforms, TRa1, TRb1, and TRb2, that are ex-
pressed in a tissue-specific fashion and that regulate a spectrum
of metabolic and developmental functions. The TRb isoforms10 Cell Metabolism 8, July 2008 ª2008 Elsevier Inc.have been shown to play essential roles in the regulation of the
hypothalamic-pituitary-thyroid axis, development of the auditory
and color visual systems, and the regulation of cholesterol me-
tabolism in the liver. In contrast, the TRa1 isoform is more widely
expressed, including in the heart, muscle, intestine, bone, and
brain, and it has been shown to be critical for thermogenesis
based in part on its role in brown adipose tissue (Forrest and
Vennstrom, 2000).
Much of our knowledge of thyroid hormone action has been
gained from mouse knockout studies as well as from studies of
the human syndrome of resistance to thyroid hormone (RTH) in
which mutant TRb proteins, defective in T3 binding, display dom-
inant negative activity. While mutations in TRb are known in hu-
mans, inherited mutations in TRa1 have not been identified to
date. However, a number of mouse models have now been de-
veloped with mutations analogous to those found in RTH
knocked into the mouse TRa1 locus. While each of these animal
models has a different phenotype, based on the specific muta-
tion introduced, each model clearly has a significant metabolic
phenotype, demonstrating the importance of TRa1 in body
weight regulation as well as adipocyte function.
As outlined by Bjorn Vennstrom (Karolinska Institute), mice
that are heterozygous for a TRa1R384C mutation are hypermet-
abolic with increased oxygen consumption, have decreased fat
depots, and are resistant to diet-induced obesity. This result
was surprising since animals possessing this mutant receptor
would be expected to portray a phenotype consistent with hypo-
thyroidism—not hyperthyroidism—as the mutant receptor binds
T3 poorly, and would be expected to inhibit wild-type TRa1 func-
tion. In this case, the mutant receptor appears to exert its effect
centrally by regulating sympathetic outflow and enhancing
brown adipose tissue (BAT) function, which in turn consumes
lipid stores in white adipose tissue (WAT) and other organs, to
supply BAT with further substrate (Sjogren et al., 2007). The iden-
tification of the hypothalamic neuronal target of this unliganded
TR could be important in our understanding of key hypothalamic
pathways that regulate energy expenditure via control of the
sympathetic nervous system.
Another mutant model (TRa1PV) developed in the laboratory of
Sheue-Yann Cheng (National Institutes of Health) showed re-
duced WAT mass across a variety of depots as well as reduced
body weight and short stature. Interestingly, the mutant TRa1PV
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PPARg, a critical nuclear receptor for adipocyte development,
and to block its transcriptional activity in WAT (Ying et al.,
2007). Thus, downstream targets of PPARg are downregulated
in vivo and adipogenesis can be impaired in vitro, implying that
the mutant TRa1 has targeted a novel pathway that regulates
adipocyte development and function.
In contrast to the lean phenotypes of the two mutant models
described above, the TRa1P398H model presented by Gregory
Brent (University of California, Los Angeles, Los Angeles, CA) is
obese with increased visceral adiposity and hepatic steatosis.
Importantly, this mutation blocks norepinephrine-mediated lipol-
ysis in WAT by potentially downregulating hormone-sensitive
lipase in adipose tissue. In the liver, TRa1P398H is recruited to
PPARa response elements and blocks PPARa binding, which re-
duces expression of key enzymes regulating fatty acid oxidation,
thus allowing the development of hepatic steatosis (Liu et al.,
2007). Interestingly, the other TRa1 mutants described above
do not share this property when tested in primary hepatocytes.
Taken together, these three models define a critical role for thy-
roid hormone receptors in metabolic regulation via actions in
both BAT and WAT, the liver, and centrally in the hypothalamus.
These mouse models demonstrate that TRa1 and its T3 ligand
are likely to have significant effects on metabolism. The pheno-
typic variations may reflect the different location of the mutations
in TRa1, with each having differential effects on interactions with
various transcriptional cofactors that modify TRa1 activity in
specific target cell types. Identification of these TRa1 cell-type
Figure 1. Cellular Thyroid Hormone Action Is Regulated at Multiple
Levels
In the circulation, T4, the main product of the thyroid gland, is much more
abundant than T3, the primary active form of the hormone. The transport of
T4 and T3 into target tissues and cells is probably regulated by multiple trans-
porters, one of which is the recently identified monocarboxylate 8 transporter.
Within target tissues, T4 can be converted to T3 by type 2 deiodinase (D2) to
amplify local T3 levels. Alternatively, T4 and T3 can be inactivated by type 3 de-
iodinase (D3), producing rT3 and T2, respectively. Deiodinases may regulate
local tissue hormone levels in the immediate target cell or though a para-
crine-like mechanism in nearby cell types in the tissue. Intracellular T3 exerts
major actions by regulating the transcriptional activity of nuclear thyroid hor-
mone receptors (TR), which can bind as homodimers or heterodimers with ret-
inoid X receptors to the regulatory regions of target genes. T3 binding modu-
lates TR conformation to activate or repress transcription by recruiting
coregulatory proteins such as members of the corepressor (CoR) or coactiva-
tor (CoA) superfamilies.specific pathways could yield new targets for the therapy of
metabolic disease.
Local Controls Govern Thyroid Hormone Action
The measurement of circulating levels of T4 and T3 in concert with
TSH has long been considered the standard for assessing thyroid
status.However, it is increasingly clear that cellular T3 levels within
the target tissue can be modulated by two separate mechanisms
that profoundly affect cellular metabolism. The first mechanism
involves transporters for the uptake of T4 and/or T3 into target tis-
sues. The physiological importance of regulation of hormone
access to target cells was recently highlighted by the identification
of a T3 transporter, the monocarboxylate transporter 8 (MCT8),
which plays a key role in allowing T3 to enter the brain and target
neurons. In humans, mutations in the X-linked MCT8 gene cause
a profound neurologic phenotype associated with high-serum T3
levels (Dumitrescu et al., 2004; Friesema et al., 2004). It seems
likely that transporters will be found to play a role in contributing
to the hormonal sensitivity of a wider variety of tissues.
The second pathway regulates the local production of T3 and
is controlled by three separate monodeiodinases. Deiodination
has long been recognized as important in regulating the periph-
eral conversion of T4 into the active ligand T3, as well as in the
removal of ligand by the conversion of T3 into the inactive metab-
olite T2. Recent advances suggest that specific cellular expres-
sion of individual deiodinases profoundly influences the develop-
ment and function of a variety of systems, including tissues that
mediate metabolism and energy expenditure (Bianco and Kim,
2006; Hernandez et al., 2006).
The role of the type 2 deiodinase (D2), which promotes the
conversion of T4 to T3, in the regulation of energy expenditure
was demonstrated by Antonio Bianco (Brigham and Women’s
Hospital, Boston, MA), who showed that D2 expression in BAT
plays a major role in mediating the function of bile acids in pre-
venting obesity and in increasing energy expenditure. Bile acids,
now recognized to signal through the nuclear receptor FXR and
the G protein-coupled receptor TGR-5, are able to increase
energy expenditure in BAT by stimulating D2 activity thereby
increasing cellular T3 concentrations. The effect of bile acids is
lost in D2 knockout mice (Watanabe et al., 2006). Thus, local
activation of D2 in BAT may be viewed as a candidate step for
therapeutic intervention to promote energy expenditure. In addi-
tion to its role in bile-acid signaling, D2 appears to play a critical
role in brown fat development and is able to influence the devel-
opment of insulin signaling, again highlighting the critical role of
cellular T3 levels in whole-body metabolism. The link between
insulin and T3 signaling was also shown by Mary Elizabeth Patti
(Joslin Diabetes Center, Boston, MA), whose work has sug-
gested that decreased T3 action is intimately linked to cellular
lipid excess and may contribute to the impaired oxidative metab-
olism characteristic of diabetes.
While D2 increases local T3 production, the type 3 deiodinase
(D3) converts T4 and T3 into the minimally active metabolites rT3
and T2, respectively. In humans, placental D3 plays a key role in
preventing high levels of T3 from reaching the developing fetus;
D3 is also implicated in the euthyroid sick syndrome, where its
increased activity lowers metabolism in critically ill patients. In
addition, when overexpressed in tumors, D3 can lead to sys-
temic hypothyoidism with very low T3 levels (‘‘consumptiveCell Metabolism 8, July 2008 ª2008 Elsevier Inc. 11
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Hospital, Boston, MA), in the heart the local expression of D3
can also be regulated by hypoxia. The pathway to increased
D3 expression is mediated by the transcription factor hypoxia
inducible factor 1 (HIF-1), which binds to the D3 promoter to
activate its expression. To demonstrate a physiologic role of
induced D3 expression, Huang and colleagues turned to a rat
model of a failing heart in which there was hypertrophy of the
right ventricle. In this model, they found that D3 expression
was increased in the hypertrophied myocardium and, impor-
tantly, T3 signaling was markedly reduced. Thus, the hypoxic in-
duction of D3 appears to allow the failing myocardium to adjust
metabolically to the physiologic stress present (Simonides et al.,
2008). This local control of T3 action is likely to occur in other tis-
sues where HIF-1 is induced, either by hypoxic stress or perhaps
by an oncogenic signaling process.
Thyroid Hormone Analogs as Therapeutic Agents
Thyroid hormone signaling is recognized as a prime regulator of
circulating total and LDL cholesterol levels clinically, principally
due to its actions on the liver. Indeed, hyperthyroidism is associ-
ated with low-serum cholesterol levels and hypothyroidism with
high-serum cholesterol levels. However, T4 and T3 have not been
considered as effective therapeutic options for the treatment of
hypercholesterolemia because of systemic side effects in the
heart, muscle, and bone, which are well described in hyperthy-
roidism. As introduced by Thomas Scanlan (Oregon Health Sci-
ences University, Portland, OR), the TRb-selective analog GC-1
has therapeutic potential given that TRb expression is predomi-
nant in the liver but is less prominent in the heart, bone, and mus-
cle. Indeed, GC-1 binds with at least 4-fold higher affinity to TRb1
than TRa1 and is also selectively taken up by the liver (Baxter
et al., 2004). Preclinical studies in rodents and monkeys, per-
formed by a variety of laboratories, demonstrate a significant
cholesterol-lowering effect of GC-1 without systemic side ef-
fects of hyperthyroidism. Importantly, GC-1 has now entered
single- and multiple-dose phase 1 clinical trials in humans and
is apparently well tolerated and shows a targeted effect.
The therapeutic potential of TRb isoform-specific thyroid hor-
mone analogs was further highlighted by Paul Webb (Methodist
Hospital Research Institute, Houston, TX), who showed data
demonstrating that thyroid hormone analogs including another
compound, KB2115, had additional effects in animal studies
that included a loss of adipose tissue and weight, lowering of
fasting blood glucose, and improved insulin signaling. This com-
pound has completed phase 1 trials and has entered phase 2
clinical trials in humans and appears to lower LDL-cholesterol
levels without having adverse cardiac effects (Berkenstam
et al., 2008). It remains unclear why these analogs can have dis-
tinct actions on target tissues separate from the liver, but this
may involve indirect or direct influences on metabolism in other
target tissues such as fat and muscle. The final tissue-specific
actions of some agents may reflect a ‘‘composite’’ mechanism
that includes selective tissue distribution and uptake, as well
as preference for a receptor isoform within a target cell. Poten-
tially, the receptor’s interaction with a given agent may also be
influenced by the presence of tissue-specific transcriptional co-
factors. While thyroid hormone analogs have entered clinical tri-
als, much remains to be learned about their mechanism of action12 Cell Metabolism 8, July 2008 ª2008 Elsevier Inc.and safety profile. These analogs provide evidence that selective
modulation of TR isoform action has potential therapeutic benefit
in the management of hypercholesterolemia and potentially
other metabolic disorders.
Future Directions
Though we have a much clearer understanding of how thyroid
hormone is produced and acts since Murray first administered
it to humans in 1891, our therapeutic armamentarium for modu-
lating thyroid hormone signaling pathways in vivo has seen rela-
tively little change. This research summit illustrated multiple new
pathways that are controlled by thyroid hormone receptor iso-
forms and by the transporters and deiodinases that control the
cellular availability of ligand. New therapeutic agents, including
the thyroid hormone analogs or potentially bile acids, may be de-
signed to activate or inactivate T3 signaling in a cell-specific
fashion to regulate metabolic function. As we learn more of spe-
cific transporters for T4 and T3, there may be further scope for in-
tervention at the level of hormone uptake in target tissues. Fur-
ther work to identify new pathways controlled by T3 in different
cell types may yield additional targets to pursue for therapies
for a wide variety of metabolic diseases.
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